Lakefront Biotherapeutics (LKFT) Profit After Tax Growth (3y) (2017 - 2026)

Lakefront Biotherapeutics (LKFT) Profit After Tax Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Lakefront Biotherapeutics 1.86 Bn -1.54 Bn 1.91 Mn 47.98%

Historic Data

Download Data
DateValue
Mar 31, 2026 47.98%
Dec 31, 2025 79.41%
Sep 30, 2025 -186.15%
Jun 30, 2025 116.26%
Mar 31, 2025 -126.45%
Dec 31, 2024 35.00%
Sep 30, 2024 46.05%
Jun 30, 2024 39.91%
Mar 31, 2024 56.54%
Dec 31, 2023 179.52%
Sep 30, 2023 29.52%
Jun 30, 2023 26.07%
Mar 31, 2023 40.18%
Dec 31, 2022 -21.51%
Sep 30, 2022 -56.71%
Jun 30, 2022 26.15%
Mar 31, 2022 35.08%
Dec 31, 2021 -87.49%
Sep 30, 2021 -112.04%
Jun 30, 2021 -32.56%